Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003025718 | SCV003313521 | uncertain significance | Developmental and epileptic encephalopathy 94 | 2022-02-09 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with CHD2-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). This variant is present in population databases (rs764332853, gnomAD 0.007%). This sequence change replaces threonine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 604 of the CHD2 protein (p.Thr604Asn). |
Ambry Genetics | RCV003012275 | SCV003562188 | uncertain significance | Inborn genetic diseases | 2021-03-09 | criteria provided, single submitter | clinical testing | The c.1811C>A (p.T604N) alteration is located in exon 16 (coding exon 15) of the CHD2 gene. This alteration results from a C to A substitution at nucleotide position 1811, causing the threonine (T) at amino acid position 604 to be replaced by an asparagine (N). The p.T604N alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |